ARHGAP45

Across TCGA pan-cancer cohorts, ARHGAP45 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARHGAP45 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ARHGAP45 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP45 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and STAD are the cancer types where ARHGAP45 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
UCEC	DFS	Median	All	1.000	0.630	.025	24	view →
STAD	OS	Median	IV	0.001	0.544	<.001	18	view →
LUAD	DFS	Median	IV	0.333	0.671	.048	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.794	0.302	.034	4	view →
LIHC	DFS	Median	All	0.101	0.526	.047	3	view →
COAD	OS	Median	All	0.308	0.704	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARHGAP45–OV (DFS)

Open the OV breakdown →